Physician profile
Sandhya Mudumbi
NPI 1902249089
$1,574.68
in general payments reported to CMS, 2019-2025
22 companies · $164 in 2025
The $164 reported for 2025 was more than what 76% of Hospice and Palliative Medicine (Internal Medicine) providers received nationally (typical 2025 total: $77.77).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $215 · 2022: $285 · 2023: $449 · 2024: $461 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,074.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $458.56 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $214.65 | 2022-2025 | Calquence, Tagrisso, Imfinzi |
| Regeneron Healthcare Solutions, INC. | $132.85 | 2023-2025 | Libtayo |
| Aveo Pharmaceuticals, INC. | $121.46 | 2023-2024 | Fotivda |
| Merck Sharp & Dohme LLC | $105.75 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Eisai INC. | $93.44 | 2023 | |
| Janssen Biotech, INC. | $66.03 | 2023-2025 | Darzalex, Imbruvica, Balversa |
| Exelixis INC. | $54.20 | 2023-2025 | Cabometyx |
| Abbvie INC. | $47.39 | 2024 | |
| Novartis Pharmaceuticals Corporation | $38.85 | 2024 | |
| Seagen INC. | $28.88 | 2023 | Tukysa |
| Deciphera Pharmaceuticals INC. | $26.90 | 2024 | Qinlock |
| Emd Serono, INC. | $24.97 | 2024 | |
| Astellas Pharma US INC | $23.36 | 2024 | Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $22.28 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Morphosys, US INC. | $18.49 | 2023 | Monjuvi |
| Tersera Therapeutics LLC | $17.24 | 2022 | |
| Sumitomo Pharma America, INC. | $16.93 | 2024 | Orgovyx |
| Pharmaessentia USA Corporation | $16.84 | 2023 | Besremi |
| Alexion Pharmaceuticals, INC. | $16.05 | 2024 | Ultomiris |
| Puma Biotechnology, INC. | $15.23 | 2024 | |
| Taiho Oncology, INC. | $14.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandhya Mudumbi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.